Payment overview · 2025
General Payments
$3,889.95
73 reported records · 16 companies
Healthcare provider profile · identity verified
Benjamin Wu
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1275639502
Verified facts
What the public records show
CMS Open Payments records show Benjamin Wu received $3,889.95 in general payments during 2025 across 73 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Nexletol, Ozempic, Prolia, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 282 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 448 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synjardy by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $850.49 | 21.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $543.09 | 14.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $517.41 | 13.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $375.00 | 9.6% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $275.64 | 7.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $250.00 | 6.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $200.15 | 5.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $191.32 | 4.9% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $171.51 | 4.4% | 7 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $150.00 | 3.9% | 1 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $147.33 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.32 | 1.8% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.84 | 1.8% | 3 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $39.08 | 1.0% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.87 | 0.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.90 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,889.95 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $375.00 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $375.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $312.42 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $275.64 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $232.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $200.15 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $190.27 | 4 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $179.31 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $166.23 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $148.59 | 3 | 2025 |
Source payment records
|
|||||
| HYDRUS Microstent Normalized: hydrus microstent |
Device | Alcon Vision LLC | $147.33 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $82.77 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $70.32 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $68.84 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $66.32 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $66.22 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $5.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 353 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 448 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 282 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 110 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 309 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
282 | 62 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
110 | 72 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
353 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
448 | 73 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
95 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
96 | 71 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
309 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1749 | 320 |
| Amlodipine Besylate | Amlodipine Besylate | 1414 | 248 |
| Vascepa | Icosapent Ethyl | 1298 | 207 |
| Montelukast Sodium | Montelukast Sodium | 1215 | 263 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1108 | 220 |
| Omeprazole | Omeprazole | 891 | 253 |
| Metoprolol Succinate | Metoprolol Succinate | 868 | 141 |
| Losartan Potassium | Losartan Potassium | 821 | 148 |
| Alendronate Sodium | Alendronate Sodium | 791 | 127 |
| Trazodone Hcl | Trazodone Hcl | 768 | 158 |
| Tamsulosin Hcl | Tamsulosin Hcl | 692 | 119 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 656 | 108 |
| Diclofenac Epolamine | Diclofenac Epolamine | 631 | 120 |
| Simvastatin | Simvastatin | 602 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 596 | 148 |
| Raloxifene Hcl | Raloxifene Hcl | 586 | 98 |
| Gabapentin | Gabapentin | 570 | 134 |
| Pravastatin Sodium | Pravastatin Sodium | 540 | 89 |
| Celecoxib | Celecoxib | 521 | 226 |
| Diclofenac Sodium | Diclofenac Sodium | 451 | 148 |
| Jardiance | Empagliflozin | 448 | 73 |
| Metformin Hcl Er | Metformin Hcl | 430 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 387 | 70 |
| Ammonium Lactate | Ammonium Lactate | 357 | 135 |
| Farxiga | Dapagliflozin Propanediol | 353 | 64 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 341 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 329 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 309 | 61 |
| Metformin Hcl | Metformin Hcl | 294 | 53 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 293 | 67 |
| Meloxicam | Meloxicam | 290 | 153 |
| Meclizine Hcl | Meclizine Hcl | 284 | 163 |
| Linzess | Linaclotide | 282 | 62 |
| Donepezil Hcl | Donepezil Hcl | 276 | 46 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 262 | 89 |
| Glipizide Er | Glipizide | 250 | 49 |
| Januvia | Sitagliptin Phosphate | 231 | 40 |
| Eliquis | Apixaban | 228 | 38 |
| Azithromycin | Azithromycin | 226 | 186 |
| Allopurinol | Allopurinol | 218 | 38 |
| Finasteride | Finasteride | 216 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 213 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 93 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 205 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 202 | 34 |
| Halobetasol Propionate | Halobetasol Propionate | 191 | 123 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 189 | 26 |
| Icosapent Ethyl | Icosapent Ethyl | 185 | 72 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 181 | 86 |
| Ezetimibe | Ezetimibe | 178 | 30 |
| Isoniazid | Isoniazid | 170 | 52 |
| Azelastine Hcl | Azelastine Hcl | 166 | 78 |
| Dexlansoprazole Dr | Dexlansoprazole | 166 | 42 |
| Famotidine | Famotidine | 164 | 37 |
| Labetalol Hcl | Labetalol Hcl | 157 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 152 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 38 |
| Rifampin | Rifampin | 152 | 63 |
| Mometasone Furoate | Mometasone Furoate | 148 | 85 |
| Enalapril Maleate | Enalapril Maleate | 147 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 144 | 87 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 143 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 138 | 28 |
| Glimepiride | Glimepiride | 137 | 24 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 137 | 20 |
| Atenolol | Atenolol | 128 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 119 | 35 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 117 | 17 |
| Prolia | Denosumab | 110 | 72 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 110 | 18 |
| Fluocinonide | Fluocinonide | 106 | 60 |
| Dutasteride | Dutasteride | 100 | 14 |
| Febuxostat | Febuxostat | 99 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 23 |
| Restasis | Cyclosporine | 98 | 16 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 96 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 96 | 71 |
| Breo Ellipta | Fluticasone/Vilanterol | 95 | 17 |
| Vemlidy | Tenofovir Alafenamide | 95 | suppressed |
| Myrbetriq | Mirabegron | 94 | 19 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 93 | 17 |
| Telmisartan | Telmisartan | 93 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 92 | 37 |
| Lisinopril | Lisinopril | 91 | 14 |
| Tradjenta | Linagliptin | 91 | 14 |
| Pregabalin | Pregabalin | 89 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 86 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 15 |
| Sucralfate | Sucralfate | 84 | 36 |
| Furosemide | Furosemide | 80 | 26 |
| Prednisone | Prednisone | 77 | 52 |
| Colchicine | Colchicine | 71 | 25 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 70 | 12 |
| Glipizide | Glipizide | 69 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 67 | 54 |
| Sertraline Hcl | Sertraline Hcl | 64 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 20 |
| Bepotastine Besilate | Bepotastine Besilate | 62 | 38 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 62 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 60 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | 24 |
| Glyxambi | Empagliflozin/Linagliptin | 59 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 59 | suppressed |
| Acarbose | Acarbose | 58 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 39 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 52 | 19 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 52 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 24 |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 46 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 24 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 33 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Clonazepam | Clonazepam | 40 | 13 |
| Creon | Lipase/Protease/Amylase | 40 | suppressed |
| Loperamide | Loperamide Hcl | 40 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Procto-Med Hc | Hydrocortisone | 37 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Folic Acid | Folic Acid | 36 | 11 |
| Hydrocortisone | Hydrocortisone | 36 | 23 |
| Licart | Diclofenac Epolamine | 35 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Entecavir | Entecavir | 34 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 23 |
| Livalo | Pitavastatin Calcium | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 24 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 11 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 24 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 24 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 18 |
| Praluent Pen | Alirocumab | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Invokana | Canagliflozin | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 18 | 14 |
| Kerendia | Finerenone | 18 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | 14 |
| Silodosin | Silodosin | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nexletol | Bempedoic Acid | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Glipizide Xl | Glipizide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Terconazole | Terconazole | 15 | suppressed |
| Dexilant | Dexlansoprazole | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Evista | Raloxifene Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,889.95 · 73 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Brinsupri, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FASENRA, HYDRUS Microstent, JARDIANCE, Kerendia, LINZESS, MYNX CONTROL VENOUS, NEXLETOL, OTEZLA, Ozempic, PROLIA, PYRUKYND, REPATHA, TRELEGY ELLIPTA, VYALEV, Wegovy, ZENPEP, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error